Detection of cancer embryo antigen and endothelin-1 in exhaled breath condensate: A novel approach to investigate non-small cell lung cancer

Chen,Jin‑Liang; Lv,Xue‑Dong; Ma,Hang; Chen,Jian‑Rong; Huang,Jian‑An

doi:10.3892/mco.2016.902

Detection of cancer embryo antigen and endothelin-1 in exhaled breath condensate: A novel approach to investigate non-small cell lung cancer

Authors:
- Jin‑Liang Chen
- Xue‑Dong Lv
- Hang Ma
- Jian‑Rong Chen
- Jian‑An Huang
View Affiliations

Affiliations: Department of Respiratory Medicine, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China, Department of Respiration Respiratory Medicine, The Second Affiliated Hospital of Nantong University, Nantong 226001, P.R. China
Published online on: May 11, 2016 https://doi.org/10.3892/mco.2016.902
Pages: 124-128

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the clinical significance of cancer embryo antigen (CEA) and endothelin-1 (ET-1) in the exhaled breath condensate (EBC) of patients with non‑small cell lung cancer (NSCLC). EBC samples were collected from 143 patients with NSCLC and 119 healthy individuals by using an EBC collector. The CEA and ET‑1 levels in the EBC and serum were detected. The levels of CEA and ET‑1 in the serum and EBC of the NSCLC group were higher compared with those of the healthy group. The level of CEA in the EBC of the adenocarcinoma group was higher compared with that in the squamous cell carcinoma group. The levels of CEA and ET‑1 in the serum and EBC in stages III and IV were higher compared with those in stages I and II. The levels of CEA and ET‑1 in the EBC were positively correlated with those in the serum, and furthermore, they exhibited high specificity and sensitivity. Thus, these parameters may be used to diagnose lung cancer. The detection of CEA and ET‑1 in EBC may help the process of diagnosing and monitoring the progression of NSCLC.

View Figures

View References

1	Eberini I, Gianazza E, Pastorino U and Sirtori C: Assessment of individual lung cancer risk by the proteomic analysis of exhaled breath condensate. Expert Opin Med Diagn. 2:1309–1315. 2008. View Article : Google Scholar : PubMed/NCBI
2	Pillai RN and Ramalingam SS: Advances in the diagnosis and treatment of non-small cell lung cancer. Mol Cancer Ther. 13:557–564. 2014. View Article : Google Scholar : PubMed/NCBI
3	Padda SK, Burt BM, Trakul N and Wakelee HA: Early-stage non-small cell lung cancer: Surgery, stereotactic radiosurgery and individualized adjuvant therapy. Semin Oncol. 41:40–56. 2014. View Article : Google Scholar : PubMed/NCBI
4	Dalaveris E, Kerenidi T, Katsabeki-Katsafli A, Kiropoulos T, Tanou K, Gourgoulianis KI and Kostikas K: VEGF, TNF-alpha and 8-isoprostane levels in exhaled breath condensate and serum of patients with lung cancer. Lung Cancer. 64:219–225. 2009. View Article : Google Scholar : PubMed/NCBI
5	Ciebiada M, Górski P and Antczak A: Eicosanoids in exhaled breath condensate and bronchoalveolar lavage fluid of patients with primary lung cancer. Dis Markers. 32:329–335. 2012. View Article : Google Scholar : PubMed/NCBI
6	Antus B and Barta I: Exhaled breath condensate pH in patients with lung cancer. Lung Cancer. 75:178–180. 2012. View Article : Google Scholar : PubMed/NCBI
7	Chan HP, Lewis C and Thomas PS: Exhaled breath analysis: Novel approach for early detection of lung cancer. Lung Cancer. 63:164–168. 2009. View Article : Google Scholar : PubMed/NCBI
8	Mozzoni P, Banda I, Goldoni M, Corradi M, Tiseo M, Acampa O, Balestra V, Ampollini L, Casalini A, Carbognani P and Mutti A: Plasma and EBC microRNAs as early biomarkers of non-small-cell lung cancer. Biomarkers. 18:679–686. 2013. View Article : Google Scholar : PubMed/NCBI
9	Stathopoulos D, Loukides S and Syrigos K: 8-Isoprostane in exhaled breath condensate of patients with non-small cell lung cancer: The effect of chemotherapy. Anticancer Res. 34:5143–5145. 2014.PubMed/NCBI
10	Brussino L, Culla B, Bucca C, Giobbe R, Boita M, Isaia G, Heffler E, Oliaro A, Filosso P and Rolla G: Inflammatory cytokines and VEGF measured in exhaled breath condensate are correlated with tumor mass in non-small cell lung cancer. J Breath Res. 8:0271102014. View Article : Google Scholar : PubMed/NCBI
11	Dassanayake DL, Muthunayake TM, Senevirathna KH and Siribaddana A: Staging of lung cancer in a tertiary care setting in Sri Lanka, using TNM 7th edition. A comparison against TNM6. BMC Res Notes. 5:1432012. View Article : Google Scholar : PubMed/NCBI
12	Fumagalli M, Ferrari F, Luisetti M, Stolk J, Hiemstra PS, Capuano D, Viglio S, Fregonese L, Cerveri I, Corana F, et al: Profiling the proteome of exhaled breath condensate in healthy smokers and COPD patients by LC-MS/MS. Int J Mol Sci. 13:13894–13910. 2012. View Article : Google Scholar : PubMed/NCBI
13	Liu HC, Lu MC, Lin YC, Wu TC, Hsu JY, Jan MS and Chen CM: Differences in IL-8 in serum and exhaled breath condensate from patients with exacerbated COPD or asthma attacks. J Formos Med Assoc. 113:908–914. 2014. View Article : Google Scholar : PubMed/NCBI
14	Lee AL, Button BM, Denehy L, Roberts S, Bamford T, Mu FT, Mifsud N, Stirling R and Wilson JW: Exhaled breath condensate pepsin: Potential noninvasive test for gastroesophageal reflux in COPD and bronchiectasis. Respir Care. 60:244–250. 2015. View Article : Google Scholar : PubMed/NCBI
15	Corhay JL, Moermans C, Henket M, Nguyen Dang D, Duysinx B and Louis R: Increased of exhaled breath condensate neutrophil chemotaxis in acute exacerbation of COPD. Respir Res. 15:1152014. View Article : Google Scholar : PubMed/NCBI
16	Stefanska J, Sarniak A, Wlodarczyk A, Sokolowska M, Doniec Z, Bialasiewicz P, Nowak D and Pawliczak R: Hydrogen peroxide and nitrite reduction in exhaled breath condensate of COPD patients. Pulm Pharmacol Ther. 25:343–348. 2012. View Article : Google Scholar : PubMed/NCBI
17	Xiao P, Chen JR, Zhou F, Lu CX, Yang Q, Tao GH, Tao YJ and Chen JL: Methylation of P16 in exhaled breath condensate for diagnosis of non-small cell lung cancer. Lung Cancer. 83:56–60. 2014. View Article : Google Scholar : PubMed/NCBI
18	Gessner C, Kuhn H, Toepfer K, Hammerschmidt S, Schauer J and Wirtz H: Detection of p53 gene mutations in exhaled breath condensate of non-small cell lung cancer patients. Lung Cancer. 43:215–222. 2004. View Article : Google Scholar : PubMed/NCBI
19	Zou Y, Wang L, Zhao C, Hu Y, Xu S, Ying K, Wang P and Chen X: CEA, SCC and NSE levels in exhaled breath condensate-possible markers for early detection of lung cancer. J Breath Res. 7:0471012013. View Article : Google Scholar : PubMed/NCBI
20	Okamura K, Takayama K, Izumi M, Harada T, Furuyama K and Nakanishi Y: Diagnostic value of CEA and CYFRA 21-1 tumor markers in primary lung cancer. Lung Cancer. 80:45–49. 2013. View Article : Google Scholar : PubMed/NCBI
21	Cedrés S, Nuñez I, Longo M, Martinez P, Checa E, Torrejón D and Felip E: Serum tumor markers CEA, CYFRA21-1 and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC). Clin Lung Cancer. 12:172–179. 2011. View Article : Google Scholar : PubMed/NCBI
22	Grunnet M and Sorensen JB: Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer. 76:138–143. 2012. View Article : Google Scholar : PubMed/NCBI
23	Zhang WM, Zhou J and Ye QJ: Endothelin-1 enhances proliferation of lung cancer cells by increasing intracellular free Ca²⁺. Life Sci. 82:764–771. 2008. View Article : Google Scholar : PubMed/NCBI
24	Carpagnano GE, Foschino-Barbaro MP, Resta O, Gramiccioni E and Carpagnano F: Endothelin-1 is increased in the breath condensate of patients with non-small-cell lung cancer. Oncology. 66:180–184. 2004. View Article : Google Scholar : PubMed/NCBI
25	Boldrini L, Gisfredi S, Ursino S, Lucchi M, Melfi F, Mussi A, Basolo F and Fontanini G: Tumour necrosis factor-alpha: Prognostic role and relationship with interleukin-8 and endothelin-1 in non-small cell lung cancer. Int J Mol Med. 17:887–892. 2006.PubMed/NCBI